Most Recent
Ex-Keystone director Paul Chiodo is fighting a bid to subpoena his personal bank statements, arguing that Keystone's receivers are fishing for potential claims against him as they look to claw back $480 million in investor funds.
Qantas has brought a strike-out application in a class action on behalf of hundreds of thousands of customers who allegedly never received refunds after their flights were cancelled during the COVID-19 pandemic.
Insurer Marsh has successfully appealed a finding that it breached its obligation not to use documents discovered in litigation over the $7 billion collapse of supply chain finance firm Greensill in separate proceedings.
Class action settlements hit major milestones last year, with the year’s largest settlements totalling $1.6 billion and one case resolving for a historic $548.5 million.
Pointing to a pattern of non-compliance with his orders, a judge hearing a shareholder class action over the collapse of mining company Cudeco has expressed concerns about “significant" delays in the case.
A judge has ordered Australian Unity to pay a $7.1 million penalty in ASIC proceedings alleging it pumped more than $9.5 million into a risky mortgage scheme without properly vetting investors.
Binance has agreed to a $10 million penalty in ASIC’s case alleging the defunct crypto firm misclassified retail customers as eligible to invest in risky derivatives, but a judge wants more details before approving the deal.
A judge has approved a $110 million settlement in a class action against BHP over the collapse of a tailings dam, and has OK'd fees and commission reducing the sum by 50 per cent, despite concerns the costs were excessive.
A judge on Tuesday penalised Google $55 million for anti-competitive deals requiring Telstra and Optus to pre-install its search engine on Android devices, but has questioned why action wasn't taken against the telcos.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.